NCT00612118View on ClinicalTrials.gov

A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Allergic RhinitisRhinitis, Allergic, Seasonal

Interventions

DRUG

GSK256066

200mcg bd

DRUG

azelastine hydrochloride

140mcg

Trial Locations (1)

A-1150

GSK Investigational Site, Vienna

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00612118 - A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter